442 related articles for article (PubMed ID: 26149691)
1. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
Kern G; Palmer T; Ehmann DE; Shapiro AB; Andrews B; Basarab GS; Doig P; Fan J; Gao N; Mills SD; Mueller J; Sriram S; Thresher J; Walkup GK
J Biol Chem; 2015 Aug; 290(34):20984-20994. PubMed ID: 26149691
[TBL] [Abstract][Full Text] [Related]
2. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.
Huband MD; Bradford PA; Otterson LG; Basarab GS; Kutschke AC; Giacobbe RA; Patey SA; Alm RA; Johnstone MR; Potter ME; Miller PF; Mueller JP
Antimicrob Agents Chemother; 2015 Jan; 59(1):467-74. PubMed ID: 25385112
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.
Alm RA; Lahiri SD; Kutschke A; Otterson LG; McLaughlin RE; Whiteaker JD; Lewis LA; Su X; Huband MD; Gardner H; Mueller JP
Antimicrob Agents Chemother; 2015 Mar; 59(3):1478-86. PubMed ID: 25534723
[TBL] [Abstract][Full Text] [Related]
4. Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914).
Su XH; Wang BX; Le WJ; Liu YR; Wan C; Li S; Alm RA; Mueller JP; Rice PA
Antimicrob Agents Chemother; 2016 Jan; 60(1):621-3. PubMed ID: 26482313
[TBL] [Abstract][Full Text] [Related]
5. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.
Jacobsson S; Golparian D; Alm RA; Huband M; Mueller J; Jensen JS; Ohnishi M; Unemo M
Antimicrob Agents Chemother; 2014 Sep; 58(9):5585-8. PubMed ID: 24982070
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.
Biedenbach DJ; Huband MD; Hackel M; de Jonge BL; Sahm DF; Bradford PA
Antimicrob Agents Chemother; 2015 Oct; 59(10):6053-63. PubMed ID: 26195518
[TBL] [Abstract][Full Text] [Related]
7. High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.
Unemo M; Ringlander J; Wiggins C; Fredlund H; Jacobsson S; Cole M
Antimicrob Agents Chemother; 2015 Sep; 59(9):5220-5. PubMed ID: 26077246
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Activity of Sitafloxacin and Additional Newer Generation Fluoroquinolones Against Ciprofloxacin-Resistant Neisseria gonorrhoeae Isolates.
Hamasuna R; Ohnishi M; Matsumoto M; Okumura R; Unemo M; Matsumoto T
Microb Drug Resist; 2018; 24(1):30-34. PubMed ID: 28581359
[TBL] [Abstract][Full Text] [Related]
9. Target-Mediated Fluoroquinolone Resistance in
Collins JA; Oviatt AA; Chan PF; Osheroff N
ACS Infect Dis; 2024 Apr; 10(4):1351-1360. PubMed ID: 38606464
[TBL] [Abstract][Full Text] [Related]
10. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.
Mustaev A; Malik M; Zhao X; Kurepina N; Luan G; Oppegard LM; Hiasa H; Marks KR; Kerns RJ; Berger JM; Drlica K
J Biol Chem; 2014 May; 289(18):12300-12. PubMed ID: 24497635
[TBL] [Abstract][Full Text] [Related]
11. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
12. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.
Basarab GS; Kern GH; McNulty J; Mueller JP; Lawrence K; Vishwanathan K; Alm RA; Barvian K; Doig P; Galullo V; Gardner H; Gowravaram M; Huband M; Kimzey A; Morningstar M; Kutschke A; Lahiri SD; Perros M; Singh R; Schuck VJ; Tommasi R; Walkup G; Newman JV
Sci Rep; 2015 Jul; 5():11827. PubMed ID: 26168713
[TBL] [Abstract][Full Text] [Related]
13. Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.
Charrier C; Salisbury AM; Savage VJ; Duffy T; Moyo E; Chaffer-Malam N; Ooi N; Newman R; Cheung J; Metzger R; McGarry D; Pichowicz M; Sigerson R; Cooper IR; Nelson G; Butler HS; Craighead M; Ratcliffe AJ; Best SA; Stokes NR
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223393
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors.
D'Atanasio N; Capezzone de Joannon A; Di Sante L; Mangano G; Ombrato R; Vitiello M; Bartella C; Magarò G; Prati F; Milanese C; Vignaroli C; Di Giorgio FP; Tongiani S
PLoS One; 2020; 15(2):e0228509. PubMed ID: 32074119
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Strahilevitz J; Hooper DC
Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
Lapointe G; Skepper CK; Holder LM; Armstrong D; Bellamacina C; Blais J; Bussiere D; Bian J; Cepura C; Chan H; Dean CR; De Pascale G; Dhumale B; Fisher LM; Fulsunder M; Kantariya B; Kim J; King S; Kossy L; Kulkarni U; Lakshman J; Leeds JA; Ling X; Lvov A; Ma S; Malekar S; McKenney D; Mergo W; Metzger L; Mhaske K; Moser HE; Mostafavi M; Namballa S; Noeske J; Osborne C; Patel A; Patel D; Patel T; Piechon P; Polyakov V; Prajapati K; Prosen KR; Reck F; Richie DL; Sanderson MR; Satasia S; Savani B; Selvarajah J; Sethuraman V; Shu W; Tashiro K; Thompson KV; Vaarla K; Vala L; Veselkov DA; Vo J; Vora B; Wagner T; Wedel L; Williams SL; Yendluri S; Yue Q; Yifru A; Zhang Y; Rivkin A
J Med Chem; 2021 May; 64(9):6329-6357. PubMed ID: 33929852
[TBL] [Abstract][Full Text] [Related]
17. Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance.
Collins JA; Osheroff N
ACS Infect Dis; 2024 Apr; 10(4):1097-1115. PubMed ID: 38564341
[TBL] [Abstract][Full Text] [Related]
18. In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA Gyrase.
Tan CM; Gill CJ; Wu J; Toussaint N; Yin J; Tsuchiya T; Garlisi CG; Kaelin D; Meinke PT; Miesel L; Olsen DB; Lagrutta A; Fukuda H; Kishii R; Takei M; Oohata K; Takeuchi T; Shibue T; Takano H; Nishimura A; Fukuda Y; Singh SB
Antimicrob Agents Chemother; 2016 Aug; 60(8):4830-9. PubMed ID: 27246784
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.
Kohlhoff SA; Huband MD; Hammerschlag MR
Antimicrob Agents Chemother; 2014 Dec; 58(12):7595-6. PubMed ID: 25288086
[TBL] [Abstract][Full Text] [Related]
20. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
Cambau E; Matrat S; Pan XS; Roth Dit Bettoni R; Corbel C; Aubry A; Lascols C; Driot JY; Fisher LM
J Antimicrob Chemother; 2009 Mar; 63(3):443-50. PubMed ID: 19147516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
